EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Impact of RSV Preventive Strategies on Hospitalizations for Bronchiolitis in Infants

Marine Tarizzo, Julie Mesinèle, Blandine Prevost iD, Sophie Denamur, Elora Peulier-Maitre iD, Loïc Guillot iD, Nadia Nathan iD, Harriet Corvol iD

Pediatric Pulmonology · 2026-06 · 61 (6)

DOI: 10.1002/ppul.71689 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Pulmonology, online erschienen am 10.06.2026. Verfasst von Marine Tarizzo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Inserm U938, Centre de Recherche Saint-Antoine (CRSA), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Trousseau, Service de Pneumologie Pédia…. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Hospitalization, Respiratory Syncytial Virus Vaccines, Bronchiolitis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis and hospitalization in infants. Since 2023, France has implemented two preventive strategies aimed at reducing RSV burden: long‐acting monoclonal antibody nirsevimab and RSV vaccine for pregnant women, the latter becoming available from September 2024. This study aimed to assess the impact of RSV preventive strategies on the clinical severity and viral epidemiology of bronchiolitis in hospitalized infants. Material and Methods We conducted a retrospective study at Armand Trousseau University Hospital, including infants under 12 months hospitalized for a first episode of bronchiolitis between October and March during four winter seasons (2021–2025). Clinical and virological data were compared between the pre‐intervention (2021–2023) and post‐intervention (2023–2025) periods. Subgroup analyses were performed based on RSV infection and prophylaxis status.

Results

A total of 509 infants were included (292 pre‐intervention, 217 post‐intervention). Post‐intervention infants were older (median, 3.2 vs. 1.9 months, p = 0.001), required less oxygen therapy (58.5% vs. 70.9%, p < 0.001), and had shorter hospital stays (median, 3.0 vs. 5.0 days, p < 0.001). Compared with untreated infants ( n = 140), those who received nirsevimab ( n = 67) had significantly lower rates of RSV infection and viral co‐infections (OR: 0.15 (95%CI: 0.08–0.29), p < 0.001; and 40.4% vs. 25.0%, p = 0.035), while human metapneumovirus was detected more frequently (OR: 11.00 (95%CI: 3.50–34.55), p < 0.001). Discussion and Conclusion During the period following the introduction of RSV preventive strategies, a reduced hospital burden, milder clinical courses, and shifts in viral epidemiology were observed. These findings support the continued implementation of RSV immunoprophylaxis and underscore the importance of ongoing surveillance to monitor its long‐term impact.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsHospitalizationRespiratory Syncytial Virus VaccinesBronchiolitisAntiviral AgentsAntibodies, Monoclonal, HumanizedHumansRetrospective StudiesFemaleInfantFranceMaleInfant, NewbornLength of Stay

Stichwörter der Autor:innen

RSVacute bronchiolitishospitalizationinfantmaternal vaccinationnirsevimab

Substanzen

Respiratory Syncytial Virus VaccinesAntiviral AgentsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Inserm U938, Centre de Recherche Saint-Antoine (CRSA), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Trousseau, Service de Pneumologie Pédiatrique, Sorbonne Université, Paris, France.
  • Laboratory of Childhood Genetic Diseases, Inserm UMR_S933, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Trousseau, Service de Pneumologie Pédiatrique, Sorbonne Université, Paris, France.

ORCID-Profile: Blandine Prevost, Elora Peulier-Maitre, Loïc Guillot, Nadia Nathan, Harriet Corvol

Zitieren

APA

Tarizzo, M., Mesinèle, J., Prevost, B., Denamur, S., Peulier-Maitre, E., Guillot, L., Nathan, N., & Corvol, H. (2026). Impact of RSV Preventive Strategies on Hospitalizations for Bronchiolitis in Infants. Pediatric Pulmonology, 61(6). https://doi.org/10.1002/ppul.71689

Vancouver

Tarizzo M, Mesinèle J, Prevost B, Denamur S, Peulier-Maitre E, Guillot L, et al. Impact of RSV Preventive Strategies on Hospitalizations for Bronchiolitis in Infants. Pediatric Pulmonology. 2026;61(6). doi:10.1002/ppul.71689

BibTeX
@article{Tarizzo2026,
  author = {Tarizzo, Marine and Mesinèle, Julie and Prevost, Blandine and Denamur, Sophie and Peulier-Maitre, Elora and Guillot, Loïc and Nathan, Nadia and Corvol, Harriet},
  title = {Impact of RSV Preventive Strategies on Hospitalizations for Bronchiolitis in Infants},
  journal = {Pediatric Pulmonology},
  year = {2026},
  volume = {61},
  number = {6},
  doi = {10.1002/ppul.71689}
}
Kostenlos starten →